However, Dupilumab led to improvement in abdominal pain and iron deficiency anemia with endoscopic and histologic improvements (Table 3 and Table 4). The second patient with further jejunal ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

In addition, dupilumab treatment had a significant improvement in AR symptoms based on reduced TNSS, VAS and MiniRQLQ scores. After 16 weeks of dupilumab treatment, the blood eosinophil count, ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Aim To identify risk factors for the development of dupilumab-induced ocular surface disease (DIOSD) in adult patients with atopic dermatitis (AD) and describe outcomes of treatment. Methods A ...

Abstract. Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events.Dupilumab has emerged as an alternative therapeutical ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...